AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 26291797 — intervention group
Group type: EXPERIMENTAL
Intervention: CC plus NAC
Number of subjects: 120
Study 26291797 — intervention group
Group type: COMPARATOR
Intervention: CC only
Number of subjects: 120
Study 26291797 — intervention group
Group type: COMPARATOR
Intervention: CC plus metformin
Number of subjects: 120
Study 22395265 — intervention group
Group type: EXPERIMENTAL
Intervention: Cycle ergometer warm-up, dynamic stretch component, heavy back squats
Number of subjects: 16
Study 22395265 — intervention group
Group type: EXPERIMENTAL
Intervention: Dynamic stretch component
Number of subjects: 16
Study 22395265 — intervention group
Group type: EXPERIMENTAL
Intervention: Heavy back squats
Number of subjects: 16
Study 22395265 — intervention group
Group type: COMPARATOR
Intervention: Active warm-up
Number of subjects: 16
Study 17577032 — intervention group
Group type: EXPERIMENTAL
Intervention: Lomeguatrib (LM) and Temozolomide (TMZ) at doses of 40 to 80 mg LM and 125 mg/m2 TMZ
Number of subjects: 104
Study 17577032 — intervention group
Group type: COMPARATOR
Intervention: Temozolomide (TMZ) at a dose of 200 mg/m2
Number of subjects: 104
Study 17577032 — intervention group
Group type: EXPERIMENTAL
Intervention: Lomeguatrib (LM) and Temozolomide (TMZ) after progression on TMZ
Number of subjects: 104
Study 17577032 — intervention group
Group type: EXPERIMENTAL
Intervention: Lomeguatrib (LM) and Temozolomide (TMZ)
Number of subjects: 104
Study 17577032 — intervention group
Group type: COMPARATOR
Intervention: Temozolomide (TMZ)
Number of subjects: 104
Study 14652839 — intervention group
Group type: EXPERIMENTAL
Intervention: First clamping of the proximal aorta
Number of subjects: 40
Study 14652839 — intervention group
Group type: COMPARATOR
Intervention: First clamping of the iliac vessels
Number of subjects: 40
Study 14652839 — intervention group
Group type: EXPERIMENTAL
Intervention: Current smokers (sub-group analysis)
Number of subjects: 40
Study 11450069 — intervention group
Group type: EXPERIMENTAL
Intervention: Neuromuscular Blocking Agents (NBA)
Number of subjects: 427
Study 11450069 — intervention group
Group type: COMPARATOR
Intervention: No Neuromuscular Blocking Agents (Control)
Number of subjects: 427
Study 9349334 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical doxepin
Number of subjects: 0
Study 9349334 — intervention group
Group type: COMPARATOR
Intervention: Oral terfenadine
Number of subjects: 0
Study 8451599 — intervention group
Group type: EXPERIMENTAL
Intervention: Glucagon infusion (5 ng kg‐1 min‐1)
Number of subjects: 20
Study 8451599 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 3534861 — intervention group
Group type: EXPERIMENTAL
Intervention: Dietary sodium restriction for 16 weeks
Number of subjects: 0
Study 3534861 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium repletion for 1 month
Number of subjects: 0
Study 30882703 — intervention group
Group type: EXPERIMENTAL
Intervention: Huangqi Guizhi Wuwutang granule (HGWG)
Number of subjects: 120
Study 30882703 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 120
Study 29144812 — intervention group
Group type: EXPERIMENTAL
Intervention: Roux-en-Y gastric bypass (RYGB; n = 37)
Number of subjects: 95
Study 29144812 — intervention group
Group type: EXPERIMENTAL
Intervention: Sleeve gastrectomy (SG; n = 33)
Number of subjects: 95
Study 29144812 — intervention group
Group type: COMPARATOR
Intervention: Intensive medical therapy (IMT; n = 25)
Number of subjects: 95
Study 27555205 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol anesthesia
Number of subjects: 59
Study 27555205 — intervention group
Group type: COMPARATOR
Intervention: Sevoflurane anesthesia
Number of subjects: 59
Study 24571582 — intervention group
Group type: EXPERIMENTAL
Intervention: 3 months of leuprolide acetate injections (Group A)
Number of subjects: 56
Study 24571582 — intervention group
Group type: EXPERIMENTAL
Intervention: 6 months of leuprolide acetate injections (Group B)
Number of subjects: 56
Study 21989805 — intervention group
Group type: EXPERIMENTAL
Intervention: Smoking abstinence (24-hour abstinence)
Number of subjects: 17
Study 21989805 — intervention group
Group type: COMPARATOR
Intervention: Smoking as usual
Number of subjects: 17
Study 19462276 — intervention group
Group type: EXPERIMENTAL
Intervention: Folic acid (FNA) 3 mg IV weekly
Number of subjects: 75
Study 19462276 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin B12 1 mg IV weekly
Number of subjects: 75
Study 19462276 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of folinic acid and vitamin B12 IV weekly
Number of subjects: 75
Study 18004136 — intervention group
Group type: EXPERIMENTAL
Intervention: Topiramate
Number of subjects: 40
Study 18004136 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study 14690657 — intervention group
Group type: EXPERIMENTAL
Intervention: Distolingual alveolectomy
Number of subjects: 120
Study 14690657 — intervention group
Group type: COMPARATOR
Intervention: Tooth division technique
Number of subjects: 120
Study 12205258 — intervention group
Group type: EXPERIMENTAL
Intervention: Iron supplements
Number of subjects: 263
Study 12205258 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 263
Study 9586208 — intervention group
Group type: EXPERIMENTAL
Intervention: Belief group (trained on false belief tasks)
Number of subjects: 67
Study 9586208 — intervention group
Group type: EXPERIMENTAL
Intervention: Picture group (trained on false picture tasks)
Number of subjects: 67
Study 9586208 — intervention group
Group type: COMPARATOR
Intervention: Control group (trained on number conservation tasks)
Number of subjects: 67
Study 7707099 — intervention group
Group type: EXPERIMENTAL
Intervention: Morphine hydrochloride 10 mg orally
Number of subjects: 34
Study 7707099 — intervention group
Group type: EXPERIMENTAL
Intervention: Morphine hydrochloride 10 mg rectally
Number of subjects: 34
Study 2576257 — intervention group
Group type: EXPERIMENTAL
Intervention: GTD + EE (50 micrograms GTD + 30 micrograms EE for 6 days, 70 micrograms GTD + 40 micrograms EE for 5 days, and 100 micrograms GTD + 30 micrograms EE for 10 days)
Number of subjects: 639
Study 2576257 — intervention group
Group type: EXPERIMENTAL
Intervention: GTD + EE
Number of subjects: 639
Study 2576257 — intervention group
Group type: COMPARATOR
Intervention: NET + EE
Number of subjects: 639
Study 2576257 — intervention group
Group type: COMPARATOR
Intervention: DSG + EE
Number of subjects: 639
Study 2576257 — intervention group
Group type: COMPARATOR
Intervention: All OCs
Number of subjects: 639
Study 780062 — intervention group
Group type: EXPERIMENTAL
Intervention: Prostaglandin E2 (oral solution)
Number of subjects: 100
Study 780062 — intervention group
Group type: COMPARATOR
Intervention: Oxytocin (buccal tablets)
Number of subjects: 100
Study 30277102 — intervention group
Group type: EXPERIMENTAL
Intervention: Obinutuzumab plus CHOP (G-CHOP)
Number of subjects: 100
Study 30277102 — intervention group
Group type: EXPERIMENTAL
Intervention: Shorter duration of infusion (SDI) of obinutuzumab
Number of subjects: 100
Study 28841632 — intervention group
Group type: EXPERIMENTAL
Intervention: Usual care sedation regimen
Number of subjects: 136
Study 28841632 — intervention group
Group type: EXPERIMENTAL
Intervention: Greater than or equal to 3 DSM-5 symptoms (75th percentile)
Number of subjects: 136
Study 28841632 — intervention group
Group type: EXPERIMENTAL
Intervention: Greater than or equal to 4 Bush Francis Catatonia Screening Instrument items
Number of subjects: 136
Study 26744887 — intervention group
Group type: EXPERIMENTAL
Intervention: Real rTMS
Number of subjects: 40
Study 26744887 — intervention group
Group type: COMPARATOR
Intervention: Sham rTMS
Number of subjects: 40
Study 23920083 — intervention group
Group type: EXPERIMENTAL
Intervention: PlGF (placental growth factor)
Number of subjects: 540
Study 23920083 — intervention group
Group type: EXPERIMENTAL
Intervention: sFlt‐1 (soluble fms‐like tyrosine kinase 1)
Number of subjects: 540
Study 23920083 — intervention group
Group type: EXPERIMENTAL
Intervention: sEng (soluble endoglin)
Number of subjects: 540
Study 23920083 — intervention group
Group type: EXPERIMENTAL
Intervention: Ratio of PlGF to sEng
Number of subjects: 540
Study 23920083 — intervention group
Group type: EXPERIMENTAL
Intervention: Ratio of sFlt‐1 to PlGF
Number of subjects: 540
Study 23920083 — intervention group
Group type: EXPERIMENTAL
Intervention: Logistic model with established risk factors + ratio of PlGF to sEng
Number of subjects: 540
Study 23920083 — intervention group
Group type: EXPERIMENTAL
Intervention: Logistic model with established risk factors + ratio of sFlt‐1 to PlGF
Number of subjects: 540
Study 21121874 — intervention group
Group type: EXPERIMENTAL
Intervention: omalizumab (75-375 mg sc, q2 or q4 wk)
Number of subjects: 926
Study 21121874 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 926
Study 18809182 — intervention group
Group type: EXPERIMENTAL
Intervention: Conceptual sequencing of practice problems
Number of subjects: 72
Study 18809182 — intervention group
Group type: EXPERIMENTAL
Intervention: Well-structured procedural practice
Number of subjects: 72
Study 18809182 — intervention group
Group type: EXPERIMENTAL
Intervention: Initial procedural skills
Number of subjects: 72
Study 17491173 — intervention group
Group type: EXPERIMENTAL
Intervention: NOT Plus (Web-based adjunct)
Number of subjects: 29
Study 17491173 — intervention group
Group type: COMPARATOR
Intervention: NOT (group-based program)
Number of subjects: 29
Study 15307288 — intervention group
Group type: EXPERIMENTAL
Intervention: Magnetostimulation with weak variable magnetic field (15 microT) for 12 minutes daily for 15 days added to pharmacological therapy.
Number of subjects: 24
Study 15307288 — intervention group
Group type: COMPARATOR
Intervention: Sham exposure with the same device (no active magnetostimulation).
Number of subjects: 24
Study 11713611 — intervention group
Group type: EXPERIMENTAL
Intervention: Buspirone (0.5 mg x kg bw(‐1) orally)
Number of subjects: 35
Study 11713611 — intervention group
Group type: EXPERIMENTAL
Intervention: Buspirone with pindolol pre‐treatment (40 mg over 2 days, 0.5 mg x kg bw(‐1) on test day)
Number of subjects: 35
Study 11713611 — intervention group
Group type: COMPARATOR
Intervention: Pindolol alone (40 mg over 2 days)
Number of subjects: 35
Study 11713611 — intervention group
Group type: COMPARATOR
Intervention: Placebo with pindolol pre‐treatment
Number of subjects: 35
Study 11713611 — intervention group
Group type: COMPARATOR
Intervention: Placebo alone
Number of subjects: 35
Study 9263712 — intervention group
Group type: EXPERIMENTAL
Intervention: Endometrial ablation
Number of subjects: 0
Study 9263712 — intervention group
Group type: COMPARATOR
Intervention: Hysterectomy
Number of subjects: 0
Study 7708406 — intervention group
Group type: EXPERIMENTAL
Intervention: Peripheral electrical stimulation at 20 mA
Number of subjects: 36
Study 2439677 — intervention group
Group type: EXPERIMENTAL
Intervention: Fibrin glue
Number of subjects: 51
Study 2439677 — intervention group
Group type: COMPARATOR
Intervention: Silk sutures
Number of subjects: 51
Study 30676202 — intervention group
Group type: EXPERIMENTAL
Intervention: Ulnar-based orthotics
Number of subjects: 30
Study 30676202 — intervention group
Group type: EXPERIMENTAL
Intervention: Ulnar-based orthotics plus strengthening exercises
Number of subjects: 30
Study 30676202 — intervention group
Group type: COMPARATOR
Intervention: Placebo intervention
Number of subjects: 30
Study 29959306 — intervention group
Group type: EXPERIMENTAL
Intervention: 4% articaine with epinephrine (1:200,000)
Number of subjects: 20
Study 29959306 — intervention group
Group type: COMPARATOR
Intervention: 2% lidocaine with epinephrine (1:200,000)
Number of subjects: 20
Study 26901590 — intervention group
Group type: EXPERIMENTAL
Intervention: Stress imagery session followed by a contingency management-based relapse analogue paradigm
Number of subjects: 26
Study 24622804 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin D3 supplementation (2000 IU oral vitamin D3/d)
Number of subjects: 218
Study 24622804 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 218
Study 24622804 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin D3 supplementation
Number of subjects: 218
Study 22435438 — intervention group
Group type: EXPERIMENTAL
Intervention: Griseofulvin
Number of subjects: 75
Study 22435438 — intervention group
Group type: EXPERIMENTAL
Intervention: Terbinafine
Number of subjects: 75
Study 22435438 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluconazole
Number of subjects: 75
Study 22435438 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 75
Study 20083429 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard CPAP titration during polysomnography (PSG)
Number of subjects: 61
Study 20083429 — intervention group
Group type: EXPERIMENTAL
Intervention: Ambulatory titration using auto‐CPAP and home sleep testing
Number of subjects: 61
Study 20083429 — intervention group
Group type: COMPARATOR
Intervention: Both PSG and ambulatory groups
Number of subjects: 61
Study 20083429 — intervention group
Group type: COMPARATOR
Intervention: Not applicable
Number of subjects: 61
Study 18812608 — intervention group
Group type: EXPERIMENTAL
Intervention: BI 1356 (2.5 mg)
Number of subjects: 0
Study 18812608 — intervention group
Group type: EXPERIMENTAL
Intervention: BI 1356 (5 mg)
Number of subjects: 0
Study 18812608 — intervention group
Group type: EXPERIMENTAL
Intervention: BI 1356 (100 mg to 600 mg)
Number of subjects: 0
Study 18812608 — intervention group
Group type: EXPERIMENTAL
Intervention: BI 1356 (600 mg)
Number of subjects: 0
Study 18812608 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 16398901 — intervention group
Group type: EXPERIMENTAL
Intervention: Education session for nurses and provision of three hip protectors per resident
Number of subjects: 942
Study 16398901 — intervention group
Group type: COMPARATOR
Intervention: Control group care optimized by providing brief information and two protectors per nursing home
Number of subjects: 942
Study 16398901 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention program
Number of subjects: 942
Study 16398901 — intervention group
Group type: EXPERIMENTAL
Intervention: Sensitivity analyses for real practice implementation
Number of subjects: 942
Study 16398901 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention program with lower hip protector reimbursement levels
Number of subjects: 942
Study 14703265 — intervention group
Group type: EXPERIMENTAL
Intervention: Trained paraprofessional advocates working one-on-one with women for 10 weeks
Number of subjects: 278
Study 14703265 — intervention group
Group type: COMPARATOR
Intervention: Control condition (not specified)
Number of subjects: 278
Study 10832003 — intervention group
Group type: EXPERIMENTAL
Intervention: Verbal delayed reaction methodology with a 1.5-s foreperiod
Number of subjects: 18
Study 10832003 — intervention group
Group type: EXPERIMENTAL
Intervention: Verbal delayed reaction methodology with a 0.1-s foreperiod
Number of subjects: 18
Study 10832003 — intervention group
Group type: COMPARATOR
Intervention: Verbal delayed reaction methodology
Number of subjects: 18
Study 8826808 — intervention group
Group type: EXPERIMENTAL
Intervention: Buffy-coat poor blood
Number of subjects: 589
Study 8826808 — intervention group
Group type: COMPARATOR
Intervention: Leucocyte-depleted blood
Number of subjects: 589
Study 1467719 — intervention group
Group type: EXPERIMENTAL
Intervention: Unstructured paper questionnaire
Number of subjects: 2424
Study 1467719 — intervention group
Group type: EXPERIMENTAL
Intervention: Structured paper questionnaire
Number of subjects: 2424
Study 1467719 — intervention group
Group type: EXPERIMENTAL
Intervention: Computerised questionnaire
Number of subjects: 2424
Study 6423016 — intervention group
Group type: EXPERIMENTAL
Intervention: Capsaicin inhalation (2-65 mumol l(-1), 1 min duration)
Number of subjects: 0
Study 6423016 — intervention group
Group type: COMPARATOR
Intervention: Sodium cromoglycate inhalation
Number of subjects: 0
Study 31120846 — intervention group
Group type: EXPERIMENTAL
Intervention: Metacognitive strategy training (n = 21)
Number of subjects: 43
Study 31120846 — intervention group
Group type: COMPARATOR
Intervention: Direct skill training (n = 22)
Number of subjects: 43
Study 28184420 — intervention group
Group type: EXPERIMENTAL
Intervention: Treatment arms
Number of subjects: 2155
Study 28184420 — intervention group
Group type: COMPARATOR
Intervention: Placebo arms
Number of subjects: 2155
Study 25462877 — intervention group
Group type: EXPERIMENTAL
Intervention: Enhanced cognitive behavior therapy (CBT-E)
Number of subjects: 43
Study 23270535 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise intervention (two different doses)
Number of subjects: 112
Study 23270535 — intervention group
Group type: COMPARATOR
Intervention: No-exercise control group
Number of subjects: 112
Study 21740239 — intervention group
Group type: EXPERIMENTAL
Intervention: Sectional matrix (Standard matrix, Palodent) with wedge and separation ring (BiTine I)
Number of subjects: 45
Study 21740239 — intervention group
Group type: EXPERIMENTAL
Intervention: Sectional matrix with separation rings at both mesial and distal sides (BiTine I+II)
Number of subjects: 45
Study 21740239 — intervention group
Group type: COMPARATOR
Intervention: Walser matrix (O-form)
Number of subjects: 45
Study 19249933 — intervention group
Group type: EXPERIMENTAL
Intervention: Cooling cap (Discrete Cerebral Hypothermia System) for 24 hours, then rewarmed over 24 hours.
Number of subjects: 25
Study 19249933 — intervention group
Group type: COMPARATOR
Intervention: Control group (no cooling cap).
Number of subjects: 25
Study 16752240 — intervention group
Group type: EXPERIMENTAL
Intervention: Distension of pelvic structures
Number of subjects: 50
Study 16752240 — intervention group
Group type: COMPARATOR
Intervention: Counseling (Control)
Number of subjects: 50
Study 12059825 — intervention group
Group type: EXPERIMENTAL
Intervention: Laryngeal mask airway
Number of subjects: 20
Study 12059825 — intervention group
Group type: EXPERIMENTAL
Intervention: Uncuffed tracheal tube
Number of subjects: 20
Study 12059825 — intervention group
Group type: COMPARATOR
Intervention: Both devices
Number of subjects: 20
Study 10512899 — intervention group
Group type: EXPERIMENTAL
Intervention: Good functional outcome (Barthel Index >/=50 points)
Number of subjects: 223
Study 10512899 — intervention group
Group type: COMPARATOR
Intervention: Poor functional outcome (Barthel Index <50 points)
Number of subjects: 223
Study 7552558 — intervention group
Group type: EXPERIMENTAL
Intervention: Assertive community treatment
Number of subjects: 0
Study 7552558 — intervention group
Group type: COMPARATOR
Intervention: High-quality case management
Number of subjects: 0
Study 2032101 — intervention group
Group type: EXPERIMENTAL
Intervention: Hand sewn ileoanal anastomosis with mucosectomy (group A)
Number of subjects: 32
Study 2032101 — intervention group
Group type: COMPARATOR
Intervention: Stapled ileoanal anastomosis without mucosectomy (group B)
Number of subjects: 32
Study 6459547 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 percent IDU in DMSO
Number of subjects: 46
Study 6459547 — intervention group
Group type: COMPARATOR
Intervention: DMSO alone
Number of subjects: 46
Study 6403323 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 mg ergotamine tartrate
Number of subjects: 20
Study 6403323 — intervention group
Group type: EXPERIMENTAL
Intervention: 6 mg ergotamine tartrate
Number of subjects: 20
Study 30169665 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive intervention (IPC + CM + MM)
Number of subjects: 2400
Study 30169665 — intervention group
Group type: COMPARATOR
Intervention: Nonintensive intervention (standard nutrition counseling + less intensive CM and MM)
Number of subjects: 2400
Study 26423213 — intervention group
Group type: EXPERIMENTAL
Intervention: Anomalous evidence (varying amounts)
Number of subjects: 0
Study 26423213 — intervention group
Group type: EXPERIMENTAL
Intervention: Convergent evidence (multiple types)
Number of subjects: 0
Study 26423213 — intervention group
Group type: EXPERIMENTAL
Intervention: Presentation of an alternative theory
Number of subjects: 0
Study 26423213 — intervention group
Group type: EXPERIMENTAL
Intervention: Anomalous evidence (replicating)
Number of subjects: 0
Study 24836213 — intervention group
Group type: EXPERIMENTAL
Intervention: Clopidogrel 75 mg daily for three months
Number of subjects: 0
Study 24836213 — intervention group
Group type: COMPARATOR
Intervention: Placebo daily for three months
Number of subjects: 0
Study 22964973 — intervention group
Group type: EXPERIMENTAL
Intervention: 2-fold illumination (20 and 80 J/cm2)
Number of subjects: 247
Study 22964973 — intervention group
Group type: COMPARATOR
Intervention: Single illumination (75 J/cm2)
Number of subjects: 247
Study 20424458 — intervention group
Group type: EXPERIMENTAL
Intervention: Naltrexone implants
Number of subjects: 46
Study 20424458 — intervention group
Group type: COMPARATOR
Intervention: Methadone treatment
Number of subjects: 46
Study 18418029 — intervention group
Group type: EXPERIMENTAL
Intervention: Desloratadine (standard dose) during association phase
Number of subjects: 30
Study 18418029 — intervention group
Group type: COMPARATOR
Intervention: Water (placebo) during evocation trial
Number of subjects: 30
Study 18418029 — intervention group
Group type: EXPERIMENTAL
Intervention: Novel-tasting drink with placebo pill (CS group) during evocation trial
Number of subjects: 30
Study 18418029 — intervention group
Group type: EXPERIMENTAL
Intervention: Water with desloratadine (drug group) during evocation trial
Number of subjects: 30
Study 16000277 — intervention group
Group type: EXPERIMENTAL
Intervention: Dipyridamole-induced ischemic ECG changes
Number of subjects: 629
Study 16000277 — intervention group
Group type: COMPARATOR
Intervention: Nonischemic ECG group
Number of subjects: 629
Study 12888045 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical betaxolol (twice daily)
Number of subjects: 37
Study 12888045 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 37
Study 10595045 — intervention group
Group type: EXPERIMENTAL
Intervention: Five-minute foot massage
Number of subjects: 25
Study 8917061 — intervention group
Group type: EXPERIMENTAL
Intervention: Remacemide hydrochloride 300 mg twice daily for 14 days
Number of subjects: 10
Study 8917061 — intervention group
Group type: COMPARATOR
Intervention: Placebo treatment
Number of subjects: 10
Study 1869343 — intervention group
Group type: EXPERIMENTAL
Intervention: 25 mg diphenhydramine
Number of subjects: 20
Study 1869343 — intervention group
Group type: COMPARATOR
Intervention: Placebo vehicle
Number of subjects: 20
Study 7165555 — intervention group
Group type: EXPERIMENTAL
Intervention: Acetate dialysis
Number of subjects: 7
Study 7165555 — intervention group
Group type: COMPARATOR
Intervention: Bicarbonate dialysis
Number of subjects: 7
Study 31015317 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient-Oncologist dyads
Number of subjects: 581
Study 31015317 — intervention group
Group type: EXPERIMENTAL
Intervention: Caregiver-Oncologist dyads
Number of subjects: 581